{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Resistant+Solid+Malignancies", "query": { "condition": "Resistant Solid Malignancies" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 189, "total_pages": 19, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Resistant+Solid+Malignancies&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-11T06:20:55.515Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04052204", "title": "Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Squamous Cell Carcinoma of the Head and Neck (SCCHN)", "Metastatic Castration Resistant Prostate Cancer (mCRPC)" ], "interventions": [ { "name": "avelumab", "type": "DRUG" }, { "name": "Bempegaldesleukin", "type": "DRUG" }, { "name": "talazoparib", "type": "DRUG" }, { "name": "enzalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2019-12-30", "completion_date": "2020-09-29", "has_results": true, "last_update_posted_date": "2021-10-14", "last_synced_at": "2026-09-11T06:20:55.515Z", "location_count": 1, "location_summary": "Rochester, New York", "locations": [ { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04052204" }, { "nct_id": "NCT07145255", "title": "Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Prostate Cancer Castration-resistant Prostate Cancer", "Breast Cancer", "Colo-rectal Cancer", "Lung Cancer (Non-Small Cell)", "Pancreas Cancer, Duct Cell Adenocarcinoma" ], "interventions": [ { "name": "ADC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MBrace Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2025-09-03", "completion_date": "2029-12-30", "has_results": false, "last_update_posted_date": "2026-02-17", "last_synced_at": "2026-09-11T06:20:55.515Z", "location_count": 7, "location_summary": "San Francisco, California • Grand Rapids, Michigan • East Brunswick, New Jersey + 4 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "East Brunswick", "state": "New Jersey" }, { "city": "Irving", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07145255" }, { "nct_id": "NCT03845166", "title": "A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasm Malignant", "Renal Cell Carcinoma", "Hormone Receptor Positive Breast Carcinoma", "Metastatic Castration-resistant Prostate Cancer", "Colorectal Cancer" ], "interventions": [ { "name": "XL092", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Avelumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Exelixis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 325, "start_date": "2019-03-20", "completion_date": "2027-05-31", "has_results": false, "last_update_posted_date": "2024-11-19", "last_synced_at": "2026-09-11T06:20:55.515Z", "location_count": 40, "location_summary": "Duarte, California • La Jolla, California • Los Angeles, California + 33 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03845166" }, { "nct_id": "NCT03729596", "title": "MGC018 With or Without MGA012 in Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Squamous Cell Carcinoma of Head and Neck", "Triple Negative Breast Cancer", "Melanoma", "Advanced Solid Tumor, Adult", "Metastatic Castrate Resistant Prostate Cancer", "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "vobramitamab duocarmazine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "MacroGenics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 143, "start_date": "2018-11-21", "completion_date": "2023-03-18", "has_results": true, "last_update_posted_date": "2025-07-31", "last_synced_at": "2026-09-11T06:20:55.515Z", "location_count": 9, "location_summary": "Santa Monica, California • Washington D.C., District of Columbia • Baltimore, Maryland + 5 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03729596" }, { "nct_id": "NCT01094288", "title": "A Phase 1 Study of Alisertib Participants With Advanced Solid Tumors Including Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel Regimen", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "Adenocarcinoma of the Prostate" ], "interventions": [ { "name": "Alisertib", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Millennium Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2010-08-17", "completion_date": "2017-01-04", "has_results": true, "last_update_posted_date": "2019-02-15", "last_synced_at": "2026-09-11T06:20:55.515Z", "location_count": 4, "location_summary": "Indianapolis, Indiana • Portland, Oregon • San Antonio, Texas + 1 more", "locations": [ { "city": "Indianapolis", "state": "Indiana" }, { "city": "Portland", "state": "Oregon" }, { "city": "San Antonio", "state": "Texas" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01094288" }, { "nct_id": "NCT03311334", "title": "A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Renal Cell Carcinoma (RCC)", "Urothelial Carcinoma", "Primary Peritoneal Cancer", "Platinum-resistant Ovarian Cancer (PROC)", "Serous Epithelial Ovarian Cancer", "Fallopian Tube Cancer" ], "interventions": [ { "name": "DSP-7888 Dosing Emulsion", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sumitomo Pharma America, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2017-12-14", "completion_date": "2022-11-29", "has_results": true, "last_update_posted_date": "2024-04-18", "last_synced_at": "2026-09-11T06:20:55.515Z", "location_count": 17, "location_summary": "Tucson, Arizona • Los Angeles, California • San Francisco, California + 14 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03311334" }, { "nct_id": "NCT07719361", "title": "A Study in Patients With Metastatic Castration-Resistant Prostate Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Castration Resistant Prostate Cancer", "mCRPC", "mCRPC (Metastatic Castration-resistant Prostate Cancer)", "Prostatic Neoplasms", "Prostatic Neoplasms, Castration-Resistant", "mCRPC or Advanced/Metastatic Solid Tumors", "mCRPC, Metastatic Castration Resistant Prostate Cancer", "Neoplasms Prostate", "Neoplasms of Prostate" ], "interventions": [ { "name": "FX-111", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Flare Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 60, "start_date": "2026-07-01", "completion_date": "2029-02-15", "has_results": false, "last_update_posted_date": "2026-08-04", "last_synced_at": "2026-09-11T06:20:55.515Z", "location_count": 10, "location_summary": "Los Angeles, California • Boston, Massachusetts • Grand Rapids, Michigan + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "East Brunswick", "state": "New Jersey" }, { "city": "Myrtle Beach", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT07719361" }, { "nct_id": "NCT03797391", "title": "A Dose Escalation With Expansion Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Neoplasms", "Neoplasm Metastasis", "Non-Small-Cell Lung Cancer" ], "interventions": [ { "name": "EMB-01", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shanghai EpimAb Biotherapeutics Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 186, "start_date": "2018-12-13", "completion_date": "2026-01-15", "has_results": false, "last_update_posted_date": "2023-05-31", "last_synced_at": "2026-09-11T06:20:55.515Z", "location_count": 3, "location_summary": "Boston, Massachusetts • Detroit, Michigan • Canton, Ohio", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Canton", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03797391" }, { "nct_id": "NCT00031681", "title": "7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Adult Primary Liver Cancer", "Carcinoma of the Appendix", "Estrogen Receptor-negative Breast Cancer", "Extensive Stage Small Cell Lung Cancer", "Gastrointestinal Stromal Tumor", "HER2-negative Breast Cancer", "Metastatic Gastrointestinal Carcinoid Tumor", "Ovarian Sarcoma", "Ovarian Stromal Cancer", "Progesterone Receptor-negative Breast Cancer", "Recurrent Adenoid Cystic Carcinoma of the Oral Cavity", "Recurrent Adult Primary Liver Cancer", "Recurrent Anal Cancer", "Recurrent Basal Cell Carcinoma of the Lip", "Recurrent Borderline Ovarian Surface Epithelial-stromal Tumor", "Recurrent Breast Cancer", "Recurrent Cervical Cancer", "Recurrent Colon Cancer", "Recurrent Endometrial Carcinoma", "Recurrent Esophageal Cancer", "Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Recurrent Extrahepatic Bile Duct Cancer", "Recurrent Gallbladder Cancer", "Recurrent Gastric Cancer", "Recurrent Gastrointestinal Carcinoid Tumor", "Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Recurrent Lymphoepithelioma of the Nasopharynx", "Recurrent Lymphoepithelioma of the Oropharynx", "Recurrent Metastatic Squamous Neck Cancer With Occult Primary", "Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Recurrent Mucoepidermoid Carcinoma of the Oral Cavity", "Recurrent Non-small Cell Lung Cancer", "Recurrent Ovarian Epithelial Cancer", "Recurrent Ovarian Germ Cell Tumor", "Recurrent Pancreatic Cancer", "Recurrent Prostate Cancer", "Recurrent Rectal Cancer", "Recurrent Salivary Gland Cancer", "Recurrent Small Cell Lung Cancer", "Recurrent Small Intestine Cancer", "Recurrent Squamous Cell Carcinoma of the Hypopharynx", "Recurrent Squamous Cell Carcinoma of the Larynx", "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity", "Recurrent Squamous Cell Carcinoma of the Nasopharynx", "Recurrent Squamous Cell Carcinoma of the Oropharynx", "Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Recurrent Verrucous Carcinoma of the Larynx", "Recurrent Verrucous Carcinoma of the Oral Cavity", "Small Intestine Adenocarcinoma", "Small Intestine Leiomyosarcoma", "Small Intestine Lymphoma", "Stage IV Adenoid Cystic Carcinoma of the Oral Cavity", "Stage IV Anal Cancer", "Stage IV Basal Cell Carcinoma of the Lip", "Stage IV Borderline Ovarian Surface Epithelial-stromal Tumor", "Stage IV Breast Cancer", "Stage IV Colon Cancer", "Stage IV Endometrial Carcinoma", "Stage IV Esophageal Cancer", "Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Stage IV Gastric Cancer", "Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Stage IV Lymphoepithelioma of the Nasopharynx", "Stage IV Lymphoepithelioma of the Oropharynx", "Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Stage IV Mucoepidermoid Carcinoma of the Oral Cavity", "Stage IV Non-small Cell Lung Cancer", "Stage IV Ovarian Epithelial Cancer", "Stage IV Ovarian Germ Cell Tumor", "Stage IV Pancreatic Cancer", "Stage IV Prostate Cancer", "Stage IV Rectal Cancer", "Stage IV Salivary Gland Cancer", "Stage IV Squamous Cell Carcinoma of the Hypopharynx", "Stage IV Squamous Cell Carcinoma of the Larynx", "Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IV Squamous Cell Carcinoma of the Nasopharynx", "Stage IV Squamous Cell Carcinoma of the Oropharynx", "Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage IV Verrucous Carcinoma of the Larynx", "Stage IV Verrucous Carcinoma of the Oral Cavity", "Stage IVA Cervical Cancer", "Stage IVB Cervical Cancer", "Triple-negative Breast Cancer", "Unresectable Extrahepatic Bile Duct Cancer", "Unresectable Gallbladder Cancer", "Unspecified Adult Solid Tumor, Protocol Specific", "Untreated Metastatic Squamous Neck Cancer With Occult Primary" ], "interventions": [ { "name": "7-hydroxystaurosporine", "type": "DRUG" }, { "name": "irinotecan hydrochloride", "type": "DRUG" }, { "name": "diagnostic laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2001-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-09-30", "last_synced_at": "2026-09-11T06:20:55.515Z", "location_count": 1, "location_summary": "Charlottesville, Virginia", "locations": [ { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00031681" }, { "nct_id": "NCT05293496", "title": "A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "Castration-Resistant Prostatic Cancer", "Malignant Melanoma", "Pancreatic Ductal Carcinoma", "Hepatocellular Cancer", "Epithelial Ovarian Cancer", "Renal Cell Carcinoma" ], "interventions": [ { "name": "vobramitamab duocarmazine", "type": "BIOLOGICAL" }, { "name": "lorigerlimab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "MacroGenics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2022-04-19", "completion_date": "2025-08-26", "has_results": false, "last_update_posted_date": "2025-10-14", "last_synced_at": "2026-09-11T06:20:55.515Z", "location_count": 10, "location_summary": "Los Angeles, California • San Francisco, California • Sarasota, Florida + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05293496" } ] }